Research programme: histamine receptor antagonists - Ziarco
Latest Information Update: 28 Jan 2019
At a glance
- Originator Pfizer
- Developer Ziarco
- Class Small molecules
- Mechanism of Action Histamine H3 receptor antagonists; Histamine H4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic rhinitis; Hypersensitivity
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for preclinical development in Allergic-rhinitis in United Kingdom (PO)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Allergy in United Kingdom (PO)
- 01 Dec 2014 Preclinical trials in Allergic rhinitis in United Kingdom (PO)